

Gemini Stock Analysis Report

Okay, I will analyze the provided stock analysis report for CIPLA.NS with the perspective of a seasoned positional equity trader focused on intermediate-term trends.

Step 1: Audit the Data

Here's my evaluation of the data quality:

Data Present:

- Daily Price Chart (3 years)
- Long-term Fundamental Analysis (4 years)
- Short-term Fundamental Analysis (6 quarters)
- Relative Strength Analysis (RS Ratios, RS Composite Score Timeline)
- EMA Crossover Summary and Chart
- Bollinger Bands Summary and Chart
- Supertrend Summary and Chart
- MACD Summary and Chart
- Volatility Squeeze Summary and Analysis
- RSI-Volume Divergence Analysis

Data Missing:

- Weekly Price Chart: This is important for a multi-month perspective.
- Detailed Volume Analysis (beyond the RSI-Volume chart): Understanding volume trends is crucial for confirming price moves.

Confidence Level: Medium. While the report provides a good amount of technical and fundamental data, the absence of weekly charts and detailed volume analysis weakens the overall confidence.

Step 2: Analyze the Setup

Here's my analysis of the setup based on the report's findings:

Price Structure: The 3-year daily price chart shows a general upward trend, but with significant volatility and periods of sideways consolidation. Recently, the price has been in a more confined range.

Trend Direction:

- **Long-Term Fundamentals:** Positive (Revenue, Net Income, ROE, EPS all growing).
- **Short-Term Fundamentals:** Mixed (Revenue, Net Income, EPS growing but ROE is negative).
- **EMA Crossover:** Indicates a short-term downtrend.
- **Supertrend:** Indicates a downtrend.
- **Relative Strength:** RS Ratio suggests neutral rating.
- **Bollinger Bands:** Trading around the middle band with a recent Sell Signal.
- **MACD:** Indicates a bullish crossover, suggesting potential upward momentum.

Momentum: Conflicting signals. MACD points to potential bullish momentum, while EMA, Supertrend, and Bollinger Bands are bearish. Volatility Squeeze analysis indicates possible explosive moves, up or down.

Gemini Stock Analysis Report

Confluence: Lack of clear confluence. The technical indicators give conflicting signals, and while the long-term fundamentals are positive, the short-term picture is less certain.

Step 3: Formulate the Recommendation

Based on the analysis, I do not recommend entering a long position in CIPLA.NS at the current time.

The conflicting technical signals create an unacceptably high level of uncertainty for a positional trade.

The absence of weekly price chart and detailed volume analysis further reduces my confidence.

While the long-term fundamentals are supportive, it's crucial to have technical confirmation for a trade with a 1-4 month horizon.

Conditional Plan

I will consider a long position in CIPLA.NS under the following conditions:

- **Condition to Buy:** Sustained price move above the supertrend value, and cross above the 50 EMA and 200 EMA, confirmed by rising volume for two consecutive days.
- **Entry Price:** INR 1555 (Hypothetical trigger)
- **Stop Loss:** INR 1500 (Hypothetical risk - placed below recent support and EMA 200)
- **Take Profit:** INR 1635 (Hypothetical target - providing a 5% target)

This conditional plan allows for a potential entry if the short-term downtrend reverses and positive momentum builds, supported by both price action and volume.

News & Analyst Targets

Okay, I will act as a stock research analyst and search for the latest news and information on CIPLA. Here are the latest updates I could find:

Here's the latest information on CIPLA, gathered as of December 20, 2025:

1. Latest News for CIPLA This Week:

- **Partnership with Pfizer:** Cipla has entered into an exclusive 5-year marketing and distribution agreement with Pfizer for four key pharmaceutical brands in India. Cipla will have exclusive rights to market, distribute, and sell Pfizer's Corex Dx & Corex LS (cough syrups), Dolonex (anti-inflammatory), Neksium (gastroenterology), and Dalacin C (anti-infective) brands in India. Pfizer will continue to manufacture and supply these medicines.
- **ESOP Allotment:** Cipla allotted 585 fully paid-up equity shares under its Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021.

2. Brokerage Upgrades and Downgrades for CIPLA:

Gemini Stock Analysis Report

- **HSBC:** Analyst Damayanti Kerai of HSBC raised the price target on Cipla Ltd. to INR1,765.00 (from INR1,740.00) while maintaining a Buy rating.
- **Nomura:** Analyst Saion Mujherjee of Nomura/Instinet raised the price target on Cipla Ltd. to INR1,810.00 (from INR1,780.00) while maintaining a Buy rating.

3. Other News Impacting CIPLA:

- **LIC increased Stake:** LIC increased its stake in Cipla to 7.055% by acquiring 2.03% shares between July 17 and November 27.
- **Acquisition:** Cipla has agreed to acquire a 100% stake in Inzpera Healthsciences, making it a wholly-owned subsidiary, to strengthen its presence in the pediatric and wellness segment.
- **New Launch:** Cipla launched a new medication.

4. Analyst Price Targets for CIPLA:

Here's a summary of the latest analyst price targets for CIPLA:

Source	Average Price Target (INR)	High Estimate (INR)	Low Estimate (INR)
Investing.com	1680.09	1875	1396
TradingView	1,670.46	1,870	1,396
TipRanks	1,786.67	1,815	1,765
Alpha Spread	1,715.26	1,968.75	1,409.96
Trendlyne	1704	N/A	N/A

Disclaimer: The analyst estimates should be considered as suggestions and not as a recommendation to buy or sell the stock.


Stock Detailed Analysis Report

CIPLA.NS

Current Price: ₹1517.10

Generated: 2025-12-20 20:44

CIPLA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	6.68%	7.88%
Net Income	Yes	No	27.93%	27.96%
ROE	Yes	No	9.52%	11.86%
EPS	Yes	No	27.89%	27.91%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.63%	0.87%
Net Income	Yes	6.20%	3.79%
ROE	No	-14.71%	-14.71%
EPS	Yes	20.58%	15.61%

CIPLA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Neutral
RS Score:	48.7/100
:	

== RS RATIOS ==:

1M RS:	0.989 [Neutral]
3M RS:	0.955 [Neutral]
6M RS:	0.953 [Neutral]
1Y RS:	1.018 [Leader]
:	




== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::

✓ Emerging RS:	1M (0.989) > 3M (0.955)
✓ Medium-term Lagging:	6M=0.953 (≤ 1.0)
✗ Performance Improving:	Not improving


Relative Strength Analysis: CIPLA.NS vs ^CNXPHARMA
Classification: Neutral
Price Performance Comparison (Normalized)



CIPLA.NS - EMA Crossover Summary

EMA 20:	1510.76
EMA 50:	1521.73
EMA 200:	1517.45
Trend Status:	Short-term Downtrend
Golden Cross Date:	2025-04-29 00:00:00
Golden Cross Price:	1541.50


CIPLA.NS EMA Crossover Analysis



CIPLA.NS - Bollinger Bands Summary

Current Price:	1517.10
Upper Band:	1534.73
Middle Band (SMA 20):	1510.53
Lower Band:	1486.33
%B:	0.6358
Band Width:	0.0320
Status:	Upper Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-10-23 00:00:00

CIPLA.NS Bollinger Bands (20, 2) Analysis




CIPLA.NS - Supertrend Summary

Status: DOWNTREND (Sell)

Supertrend Value: 1553.49

Signal Identified On: 2025-10-28


Supertrend Analysis for CIPLA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




CIPLA.NS - MACD Summary

MACD Line:	-6.07
Signal Line:	-7.03
Histogram:	0.95
Trend:	Bullish
Momentum:	Strengthening
Signal:	Bullish Crossover (Buy)
Divergences Detected:	1
└ Bullish Divergence:	Date: 2025-12-09 00:00:00, Price: 1490.60

CIPLA.NS Price






CIPLA.NS MACD (12, 26, 9)



CIPLA.NS - Volatility Squeeze Summary

BB Width:	0.0320
ATR:	19.4072
Total Signals:	26
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-15 00:00:00 (Price: 150.00)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-16 00:00:00 (Price: 149.00)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-17 00:00:00 (Price: 149.00)
Signal 4:	BB Squeeze + ATR Contraction at 2025-12-18 00:00:00 (Price: 149.00)
Signal 5:	BB Squeeze + ATR Contraction at 2025-12-19 00:00:00 (Price: 150.00)

CIPLA.NS - Volatility Squeeze Analysis



CIPLA.NS - RSI-Volume Summary

Current RSI:	51.28
Current Volume:	769045
Volume MA 20:	1111000
Bullish Divergences:	0
Bearish Divergences:	5
Bearish Div 1:	Date: 2024-10-09 00:00:00, Price: 1680.50
Bearish Div 2:	Date: 2025-08-25 00:00:00, Price: 1601.20

CIPLA.NS RSI-Volume Divergence Analysis

